Abstract: As one of the most basic and widely used instruments in the medical field, the evolution history of subcutaneous injection needle materials is almost a miniature history of modern materials science development. Since the invention of the first generation of syringes by Charles Pravaz and Alexander Wood in the mid-19th century, the material selection of injection needles has developed from simple metal processing to a high-tech field involving interdisciplinary integration of biocompatibility, mechanical properties, surface treatment and other aspects. This paper systematically reviews the evolutionary process of subcutaneous injection needle materials, focuses on the technical logic of stainless steel as the dominant material, the precise application of special alloys, the breakthrough progress of polymer materials and the development of surface engineering technology. On this basis, it further elaborates on the multi-layer structure of the international standardization system, the three major models of global regulatory pathways, the quality control pyramid of the production process, the global market pattern and competitive situation, as well as the safety and regional restructuring of the supply chain. Finally, it looks forward to the future development trends of intelligent response materials, integrated structure-function design and regulatory science. It is pointed out that the evolution of needle materials and the improvement of industry standards, regulatory systems are always centered on the core medical ethics of "achieving better therapeutic effects with minimal trauma", and the integration of new materials, new technologies and standardized management will promote the transformation of injection needles from passive drug delivery tools to active intelligent medical terminals, and provide basic guarantee for the global public health cause.

Keywords: Subcutaneous injection needle; Materials science; Industry standards; Regulatory system; Global market; Quality control

1. Introduction: The Material Revolution in Miniature Instruments

As one of the most basic and widely used instruments in the medical field, the evolution history of the material technology of subcutaneous injection needles is almost a miniature history of modern materials science development. Since Charles Pravaz and Alexander Wood invented the first generation of syringes in the mid-19th century, the material selection of injection needles has developed from simple metal processing to a high-tech field involving interdisciplinary integration of biocompatibility, mechanical properties, surface treatment and other aspects.

2. Technical Logic of the Stainless Steel-dominated Era

At present, austenitic stainless steel (especially 304 and 316L medical-grade stainless steel) accounts for about 85% of the global subcutaneous injection needle market, and there is a profound scientific and engineering logic behind this dominant position.

First, from the perspective of biocompatibility, medical stainless steel forms a dense chromium oxide (Cr₂O₃) passive film with a thickness of only 3-5 nanometers on the surface by precisely controlling the chromium (Cr) content (usually 16-18%). This film has self-healing properties; even if slightly scratched, it can be quickly reconstructed in an oxygen-rich environment. A 2018 study in the Journal of Biomaterials pointed out that this passive film makes the ion release rate of stainless steel needles when in contact with biological fluids lower than 0.1μg/cm²/week, which is much lower than the human metabolic clearance threshold.

In terms of mechanical properties, needle manufacturing faces the challenge of a "strength-toughness-elasticity" triangular balance. The wall thickness of the needle tube is usually only 0.1-0.15mm, but it has to bear the combined load of longitudinal puncture force and transverse bending force. Modern cold rolling technology can refine the stainless steel grain size to 5-10 microns, enabling the tensile strength to reach 850-1000MPa while maintaining an elongation of 15-20%. This "grain refinement strengthening" technology has made 33G (outer diameter 0.21mm) ultra-fine needles possible, with pain sensation reduced by more than 60% compared with traditional 27G needles.

3. Precise Application Scenarios of Special Alloys

In specific medical scenarios, nickel-chromium alloys and cobalt-chromium alloys show unique advantages. For example, Hastelloy containing molybdenum is used in long-term implantable drug delivery systems, and its corrosion resistance is more than 100 times that of stainless steel. A 2021 study by the Mayo Clinic showed that the level of inflammatory factors of insulin pump infusion needles using special alloys after 7 days of subcutaneous indwelling was only 1/3 of that of stainless steel needles.

The innovative application of shape memory alloys (especially Nitinol) is changing the field of interventional therapy. This alloy has superelasticity below the phase transition temperature, can be delivered into the human body through a 25G needle (0.5mm), and restores the preset shape under the action of body temperature. The latest neurointerventional catheters have achieved a compression ratio of "1.2mm expanded diameter / 0.3mm delivery diameter", making percutaneous puncture treatment of intracranial aneurysms a routine minimally invasive surgery.

4. Breakthrough Progress in Polymer Materials

The breakthrough of medical-grade polymer needles comes from three key technologies: nano-reinforcement technology, gas barrier coating and controllable degradation design.

After being reinforced with carbon nanotubes, the flexural modulus of polyetheretherketone (PEEK) can reach 15GPa, close to the level of titanium alloy. A 2023 report in Advanced Healthcare Materials showed that a PEEK composite needle developed by a German company exhibited 30% higher imaging clarity than metal needles under B-ultrasound guidance.

The development of biodegradable polymer needles is particularly striking. Polylactic-co-glycolic acid (PLGA) needles can stay under the skin for 4-8 weeks, release drugs continuously and then degrade completely. The "star-shaped microneedle array" developed by a team from the Massachusetts Institute of Technology consists of 16 biodegradable needle tips, each of which can carry different drugs to achieve precise time-sequenced controlled release.

5. The Microcosm of Surface Engineering

Modern needle surface treatment has entered the era of nanoscale precision. Diamond-like carbon (DLC) coating can reduce the friction coefficient from 0.6 to below 0.1, reducing puncture resistance by 40%. The "nano-sliding three-layer coating" developed by Terumo Corporation of Japan forms a gradient lubricating layer within 3mm of the needle tip, reducing the Visual Analog Scale (VAS) pain score of intradermal injection with a puncture depth of 1.5mm from 4.2 to 2.1.

Antibacterial surface technologies include silver nanoparticle coating, photocatalytic titanium dioxide coating, etc. Researchers in South Korea developed "Laser-Induced Periodic Surface Structures (LIPSS)", which form periodic grooves with a width of 200-500 nanometers on the needle surface, reducing the bacterial adhesion rate by 99.7% without affecting blood compatibility.

6. Industry Standards, Regulatory Systems and Global Market Pattern

6.1 Introduction: A Microcosmic Sample of Medical Device Regulation

As a Class II medical device (510(k) exempt in the United States and Class II in China), the regulatory system of subcutaneous injection needles embodies the development trends and regional differences of global medical device management. From raw material procurement to final clinical use, a single needle needs to meet more than 200 technical standards and regulatory requirements. This highly standardized process ensures the safety of more than 16 billion injection operations worldwide every year.

6.2 Multi-layer Structure of the International Standardization System

The ISO (International Organization for Standardization) standard system constitutes the basic framework of the global needle manufacturing industry. ISO 7864:2016 "Sterile hypodermic needles for single use" is the core standard, including 47 technical indicators, among which the key parameters are:

Needle tube rigidity: When a lateral force of 5N is applied, the displacement of the needle tip shall be ≤3mm

Needle tip puncture force: When puncturing a standard silicone membrane at a speed of 2mm/s, the peak force shall be ≤0.7N

Connection firmness: The connection between the needle hub and the needle tube can bear an axial tension of ≥15N

Lubricant residue: The silicone oil residue per needle shall be ≤0.5mg

ISO 23908:2011 Standard for Sharps Injury Prevention has promoted the global popularization of safety needles. This standard requires that the activation force of the safety device be between 5-20N, the activation time be ≤0.3 seconds, and the single activation success rate be ≥99%. Data from the European Agency for Safety and Health at Work shows that safety needles complying with this standard have reduced the incidence of sharps injuries among medical staff from 3.2 per 1000 bed-days to 0.8 per 1000 bed-days.

The differentiated requirements of regional standards reflect the regulatory philosophy of various regions. The US FDA follows ISO standards but adds USP <1> Water for Injection Compatibility Test, requiring the total amount of heavy metals in extracts to be ≤1ppm. The EU MDR regulation emphasizes chemical characterization, requiring extract studies to cover at least 3 batches of products and 6 months of accelerated aging. China's GB 18671-2009 adds a debris test, requiring the number of debris after shaking in 500mL of water to be ≤20 particles per needle.

6.3 Three Major Models of Global Regulatory Pathways

The US FDA 510(k) substantial equivalence pathway is the main channel for innovative needles to enter the market. Taking the "UltraSafe+ Passive Safety Needle" launched by BD in 2019 as an example, its 510(k) application materials include: 1) Technical comparison table with the marketed product (K143255); 2) Biocompatibility test (ISO 10993 series); 3) Performance data (2000 simulated use tests); 4) Human factors engineering research report (participated by 120 medical staff). The average approval cycle is 90 days, but the preliminary data preparation takes 12-18 months.

The EU MDR technical documentation system is more systematic. The technical documentation must include: Part A (Product Identification and Traceability), Part B (Design and Manufacturing Information), Part C (General Safety and Performance Requirements Checklist), Part D (Risk-Benefit Analysis), Part E (Clinical Evaluation Report). The key points of TÜV Germany's audit of safety needles include: whether the risk analysis covers the entire life cycle, whether the clinical evidence includes real-world data, and whether the post-marketing surveillance plan is feasible.

China NMPA registration requires the completion of type testing + clinical evaluation. According to the "Measures for the Administration of Medical Device Registration", safety needles need to complete type testing in 3 testing institutions, including biological evaluation (cytotoxicity ≤ Grade 1, sensitization ≤ Grade 1), performance testing (23 indicators), and validity verification (36 months of real-time aging). Clinical evaluation can adopt the same-variety comparison pathway, but at least 100 cases of comparison data need to be provided to prove non-inferiority.

6.4 Quality Control Pyramid of the Production Process

Raw material control establishes a triple guarantee system. Medical stainless steel must provide material certification (ASTM A967/A967M), and each batch of test reports must include: chemical composition (Cr 16.5-18.5%, Ni 10-14%), mechanical properties (tensile strength ≥515MPa, yield strength ≥205MPa), corrosion resistance (passing salt spray test for 72h). Polymer needle hub materials need to conduct extract studies, extract with different solvents (water, ethanol, n-hexane) at 50℃ for 72 hours, and the list of analytes covers all compound categories required by ISO 10993-18.

Process control realizes digital monitoring. In the needle tube drawing process, the online laser diameter gauge measures the outer diameter every 0.5 seconds with a control accuracy of ±0.003mm. The needle tip grinding process uses a visual inspection system, which takes 2 million-pixel images of each needle tip from 8 angles. The AI algorithm real-time identifies defects such as burrs and hooks, with a detection speed of 3000 pieces per minute and a false positive rate of <0.1%.

Terminal sterilization verification follows the overkill method. EO sterilization needs to verify: loading method (maximum density), pre-treatment (temperature 40±2℃, humidity 60%±10%, time 8h), sterilization period (EO concentration 600±30mg/L, temperature 55±2℃, time 4h), desorption period (desorption at 50℃ under ventilation conditions for 12 days to residual amount <4μg/g). A biological indicator (Bacillus subtilis var. niger, spore count 1×10⁶) shall be placed in each sterilization batch, and the sterility assurance level shall reach 10⁻⁶.

6.5 Global Market Pattern and Competitive Situation

The North American market (scale of 8.5 billion US dollars in 2023) is dominated by three companies: BD, Cardinal Health, and Becton Dickinson, with a combined share of 68%. The competition differentiation is mainly reflected in: the integrity of the safety needle product line (BD owns 18 safety mechanism patents), the market penetration rate of insulin-specific needles (Novo Nordisk accounts for 53% of the diabetes market), and the ecosystem integration with syringes/injection pens.

The European market (scale of 6.2 billion US dollars) presents a multi-polar pattern. B.Braun occupies 35% of the high-end hospital market with German manufacturing quality, and Turkey's Nurcan occupies 28% of the Eastern European market with cost advantages. The regulatory-driven green transition is obvious. In 2024, the EU will implement the Single-Use Plastics Directive, requiring the proportion of recycled materials in needle plastic components to be ≥30%.

The Asia-Pacific market (scale of 7.4 billion US dollars, annual growth rate of 11.2%) is the most dynamic. China's Weigao Group occupies 31% of the domestic market through localized innovation, and its "disposable anti-needle stick intravenous indwelling needle" reduces the needle stick injury rate from 0.37% to 0.02%. India's HMD occupies 45% of the African and South Asian markets with cost advantages (unit price 40% lower than European and American products). Japan's Terumo and Nipro maintain technological leadership in high-end niche markets (such as contrast agent needles and dialysis needles).

The trend of localized production in emerging markets is obvious. Brazil, Mexico, and Saudi Arabia require that the localization rate in government procurement be ≥40%, promoting international enterprises to set up factories locally. The African CDC promotes the establishment of a regional medical device procurement platform, reducing the unit price of needles from 0.12 US dollars to 0.07 US dollars through centralized procurement.

6.6 Supply Chain Safety and Regional Restructuring

The raw material supply chain presents a diversified layout. Medical stainless steel has shifted from being dominated by Japan and South Korea (Nippon Steel, POSCO) to multi-source (China's Taigang and Europe's Acerinox each account for 25%). In terms of polymer material supply, Covestro (Germany), SABIC (Saudi Arabia), and Kingfa Sci. & Tech. (China) form a tripartite balance. After the COVID-19 pandemic, major enterprises have increased their safety stock from 4 weeks to 12 weeks, and established a dual-supplier system for key materials.

Production layout is concentrated in regional manufacturing centers. BD has 8 needle production bases worldwide, implementing a "region-for-region" strategy: American demand is supplied by Mexican and American factories, European demand by Spanish and Czech factories, and Asian demand by Chinese and Singaporean factories. This layout reduces logistics costs by 15% and shortens order delivery time from 6 weeks to 2 weeks.

The digital upgrading of the quality audit system. Blockchain technology is applied to supplier management, and the raw material information of each batch (smelting furnace number, heat treatment records, test reports) is stored on the chain. Smart contracts automatically trigger quality audits. When the supplier performance score is lower than 85 points, the system automatically starts the on-site audit process. This model reduces the time for tracing quality problems from an average of 48 hours to 2 hours.

6.7 Future Trends of Regulatory Science

Real-World Evidence (RWE) is changing post-marketing regulation. The US FDA's "National Medical Device Surveillance System" has collected data on more than 3 million safety needles, identifying 3 new usage error patterns through machine learning. The EU EUDAMED database will be fully operational in 2025, realizing real-time sharing of adverse events across the EU.

Digital twin technology is applied to production process regulation. The digital twin of each production batch includes: equipment parameters (5000+ data points), environmental data (cleanroom particle count, temperature and humidity), and test results (size, performance, packaging). Regulatory authorities can remotely access the digital twin for virtual inspection, reducing the audit time by 60%.

Substantial progress has been made in global coordination. The "Medical Device Single Audit Program (MDSAP)" promoted by the IMDRF (International Medical Device Regulators Forum) has been accepted by the United States, Canada, Australia, Brazil, and Japan. Enterprises can meet the requirements of five countries through a single audit, reducing audit costs by 40% and time by 50%.

With the development of regulatory science and the evolution of the global market, the subcutaneous injection needle industry is transforming from "compliance-driven" to "value-driven". On the basis of ensuring safety and effectiveness, it continuously improves accessibility, affordability and environmental friendliness, providing basic guarantee for the global public health cause.

7. Future Trends of Technology Integration

Intelligent responsive materials represent the next development direction. The temperature-sensitive hydrogel coating remains solid at room temperature for easy puncture, and swells to form a "biological sealing layer" after entering the human body to prevent drug reflux. The pH-sensitive coating releases antibiotics when encountering the acidic environment of the infected site.

The integrated structure-function design is breaking through the traditional needle tube shape. The "honeycomb bionic needle tube" developed by Boston Scientific Corporation reduces the wall thickness by 30% while increasing the bending strength by 50%. The "vibratory puncture needle" designed inspired by mosquito mouthparts reduces the puncture force by 80% with micro-vibration at 150Hz.

8. Conclusion: The Return of Medical Value of Material Innovation and Standardized Development

Every material progress and the improvement of industry standards and regulatory systems correspond to a substantial improvement in clinical benefits. From the reduction of pain perception, to the improvement of injection accuracy, and then to the innovation of treatment models, the material evolution of subcutaneous injection needles and the improvement of the whole industry chain management system have always centered on the core medical ethics of "achieving better therapeutic effects with minimal trauma". In the future, with the further integration of nanotechnology, biomimetic technology, intelligent materials and regulatory science, injection needles will transform from a passive drug delivery tool to an intelligent medical terminal that actively participates in the treatment process. At the same time, the continuous improvement of global coordination of standards and regulatory systems, and the optimization of supply chain layout will further enhance the accessibility and affordability of injection needles, making greater contributions to the development of global public health.